Randomized, Double Blind, Placebo Controlled, Incomplete Crossover Single Oral Dose Escalation of PRCL-02 in Normal Healthy Volunteers (Part A) and Multiple Oral Dose Escalation in Normal Healthy Volunteers (Part B) and in Chronic Plaque Psoriasis Patients (Part C)
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs PRCL 02 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors PRCL Research Inc
- 15 Aug 2017 Planned End Date changed from 1 Aug 2017 to 9 Jan 2018.
- 15 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 9 Jan 2018.
- 19 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Aug 2017.